Jang Woo Ha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jang Woo Ha has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Sang-Won Lee
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
34 shared publications - Yong-Beom Park
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
34 shared publications - Oh Chan Kwon
Division of Rheumatology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea
18 shared publications - Jason Jungsik Song
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
9 shared publications - Jihye Chung
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
8 shared publications - Sung Soo Ahn
Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi-do, Republic of Korea
8 shared publications
Latest Publications
- 30 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7515-7524
Association between baseline systemic immune-inflammation index and subsequent stroke in ANCA-associated vasculitis
- 30 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7515-7524
Association between baseline systemic immune-inflammation index and subsequent stroke in ANCA-associated vasculitis
- Open Access
Association Between Baseline Modified Novel Fibrosis Index and Subsequent Stroke in Patients with Microscopic Polyangiitis or Granulomatosis with Polyangiitis
Background and Objectives: This study investigated whether the baseline modified novel fibrosis index (mNFI) could predict subsequent stroke in patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA). Materials and Methods: This study included 268 patients with MPA or GPA who met the inclusion and exclusion criteria. Clinical data at diagnosis were collected. Baseline Birmingham Vasculitis Activity Score (BVAS), Five-Factor Score (FFS), and earliest Vasculitis Damage Index (eVDI) were recorded as MPA/GPA-specific indices, and erythrocyte sedimentation rate and C-reactive protein (CRP) levels were recorded as acute-phase reactants. mNFI was derived by deleting the constant ‘N’ from the NFI formula and was calculated as follows: serum bilirubin (mg/dL) × (alkaline phosphatase [IU/L])2 / platelet count (× 1000/mm3) / (serum albumin [g/dL])2. Results: Among the 268 patients with MPA (70.9%) or GPA (29.1%), the median age was 62.0 years, and 64.6% were women. During a median follow-up of 55.1 months, stroke occurred in 7.1% of patients. Baseline mNFI correlated significantly with age, FFS and CRP, but not with BVAS or eVDI. Multivariable Cox proportional hazards analysis showed that baseline mNFI (hazard ratio 1.079) was independently associated with subsequent stroke alongside CRP levels. Patients with baseline mNFI ≥1.08 had a higher risk of subsequent stroke and a lower cumulative stroke-free survival rate than those with baseline mNFI < 1.08. Conclusions: Baseline mNFI was associated with subsequent stroke in patients with MPA or GPA and may represent a readily available candidate marker for cerebrovascular risk assessment. Further validation is required before its routine clinical application.
Open AccessAssociation Between Baseline Modified Novel Fibrosis Index and Subsequent Stroke in Patients with Microscopic Polyangiitis or Granulomatosis with Polyangiitis
Background and Objectives: This study investigated whether the baseline modified novel fibrosis index (mNFI) could predict subsequent stroke in patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA). Materials and Methods: This study included 268 patients with MPA or GPA who met the inclusion and exclusion criteria. Clinical data at diagnosis were collected. Baseline Birmingham Vasculitis Activity Score (BVAS), Five-Factor Score (FFS), and earliest Vasculitis Damage Index (eVDI) were recorded as MPA/GPA-specific indices, and erythrocyte sedimentation rate and C-reactive protein (CRP) levels were recorded as acute-phase reactants. mNFI was derived by deleting the constant ‘N’ from the NFI formula and was calculated as follows: serum bilirubin (mg/dL) × (alkaline phosphatase [IU/L])2 / platelet count (× 1000/mm3) / (serum albumin [g/dL])2. Results: Among the 268 patients with MPA (70.9%) or GPA (29.1%), the median age was 62.0 years, and 64.6% were women. During a median follow-up of 55.1 months, stroke occurred in 7.1% of patients. Baseline mNFI correlated significantly with age, FFS and CRP, but not with BVAS or eVDI. Multivariable Cox proportional hazards analysis showed that baseline mNFI (hazard ratio 1.079) was independently associated with subsequent stroke alongside CRP levels. Patients with baseline mNFI ≥1.08 had a higher risk of subsequent stroke and a lower cumulative stroke-free survival rate than those with baseline mNFI < 1.08. Conclusions: Baseline mNFI was associated with subsequent stroke in patients with MPA or GPA and may represent a readily available candidate marker for cerebrovascular risk assessment. Further validation is required before its routine clinical application.
- 27 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7505-7514
Baseline neutrophil-to-HDL cholesterol ratio is associated with subsequent cerebrovascular accident in patients with microscopic polyangiitis or granulomatosis with polyangiitis
- 27 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7505-7514
Baseline neutrophil-to-HDL cholesterol ratio is associated with subsequent cerebrovascular accident in patients with microscopic polyangiitis or granulomatosis with polyangiitis
- Open Access
- 20 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3414
Clinical Implications of the Age Threshold in the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Real-World Study of Patients Aged over 61 Years
Background/Objectives: The age item of the 2022 American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) criteria for Takayasu arteritis (TAK) (the 2022 ACR/EULAR criteria) limits the reclassification of TAK among patients aged over 61 who were classified as TAK according to the 1990 ACR criteria. Therefore, we evaluated the clinical significance of the age item of the 2022 ACR/EULAR criteria. Methods: We included 22 previously TAK-diagnosed patients aged over 61 (TAK patient aged >61 years) and 41 TAK-reclassified patients aged 50–60 (controls) in this study and retrospectively reviewed their medical records. We compared the satisfied items of the 2022 ACR/EULAR criteria between the two groups and further investigated whether these 22 TAK patients aged >61 years fulfilled the criteria for other relevant diseases. Results: In terms of absolute requirements, TAK patients aged >61 years were significantly older than TAK-reclassified patients aged 50–60. However, there were no further significant differences in the additional clinical and imaging criteria between the two groups. TAK patients aged >61 years exhibited a significantly higher frequency of ascending aorta involvement than TAK-reclassified patients aged 50–60 (18.2% vs. 0%, p = 0.012). Among the 22 TAK patients aged >61 years, ten were categorized as clinically isolated aortitis, and three of the ten patients with CIA could additionally be categorized as restrictively defined-isolated aortitis. Conclusions: Our findings support the need for external validation of the current age threshold in larger cohorts from different ethnic and geographical populations.
- 20 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3414
Open AccessClinical Implications of the Age Threshold in the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Real-World Study of Patients Aged over 61 Years
Background/Objectives: The age item of the 2022 American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) criteria for Takayasu arteritis (TAK) (the 2022 ACR/EULAR criteria) limits the reclassification of TAK among patients aged over 61 who were classified as TAK according to the 1990 ACR criteria. Therefore, we evaluated the clinical significance of the age item of the 2022 ACR/EULAR criteria. Methods: We included 22 previously TAK-diagnosed patients aged over 61 (TAK patient aged >61 years) and 41 TAK-reclassified patients aged 50–60 (controls) in this study and retrospectively reviewed their medical records. We compared the satisfied items of the 2022 ACR/EULAR criteria between the two groups and further investigated whether these 22 TAK patients aged >61 years fulfilled the criteria for other relevant diseases. Results: In terms of absolute requirements, TAK patients aged >61 years were significantly older than TAK-reclassified patients aged 50–60. However, there were no further significant differences in the additional clinical and imaging criteria between the two groups. TAK patients aged >61 years exhibited a significantly higher frequency of ascending aorta involvement than TAK-reclassified patients aged 50–60 (18.2% vs. 0%, p = 0.012). Among the 22 TAK patients aged >61 years, ten were categorized as clinically isolated aortitis, and three of the ten patients with CIA could additionally be categorized as restrictively defined-isolated aortitis. Conclusions: Our findings support the need for external validation of the current age threshold in larger cohorts from different ethnic and geographical populations.
- Open Access
Association Between Any Circulating ANCA Positivity at Diagnosis and Subsequent End-Stage Kidney Disease in Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Background and Objectives: This study examined whether positivity for any antineutrophil cytoplasmic antibody (ANCA) at diagnosis was associated with subsequent advanced systemic complications during follow-up in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: We retrospectively reviewed the medical records of 271 patients with MPA or GPA enrolled in the ANCA-associated vasculitis cohort at a tertiary hospital. Any ANCA positivity was defined as the presence of any of the following: myeloperoxidase-ANCA, proteinase 3-ANCA, perinuclear ANCA, or cytoplasmic ANCA. Subsequent advanced systemic complications during follow-up, such as all-cause mortality and end-stage kidney disease (ESKD), were evaluated. Results: The median age of the 271 patients with MPA or GPA was 62.0 years, and 239 and 32 were identified as ANCA-positive and ANCA-negative vasculitis, respectively. During follow-up, 47 patients (17.3%) died, and 52 (19.2%) progressed to ESKD. In a cross-sectional comparative analysis, ESKD occurred significantly more frequently in ANCA-positive patients than in ANCA-negative patients. Among the five subsequent advanced systemic complications of MPA and GPA, ANCA-negative patients exhibited a significantly higher cumulative ESKD-free survival rate than ANCA-positive patients. However, in multivariable Cox proportional hazards analysis adjusted for age, sex, AAV subtype, and baseline serum creatinine, ANCA positivity was not independently associated with subsequent ESKD. Conclusions: Any ANCA positivity at diagnosis was associated with subsequent ESKD in unadjusted analyses but was not an independent predictor after adjustment for baseline renal function and other clinically relevant covariates.
Open AccessAssociation Between Any Circulating ANCA Positivity at Diagnosis and Subsequent End-Stage Kidney Disease in Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Background and Objectives: This study examined whether positivity for any antineutrophil cytoplasmic antibody (ANCA) at diagnosis was associated with subsequent advanced systemic complications during follow-up in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: We retrospectively reviewed the medical records of 271 patients with MPA or GPA enrolled in the ANCA-associated vasculitis cohort at a tertiary hospital. Any ANCA positivity was defined as the presence of any of the following: myeloperoxidase-ANCA, proteinase 3-ANCA, perinuclear ANCA, or cytoplasmic ANCA. Subsequent advanced systemic complications during follow-up, such as all-cause mortality and end-stage kidney disease (ESKD), were evaluated. Results: The median age of the 271 patients with MPA or GPA was 62.0 years, and 239 and 32 were identified as ANCA-positive and ANCA-negative vasculitis, respectively. During follow-up, 47 patients (17.3%) died, and 52 (19.2%) progressed to ESKD. In a cross-sectional comparative analysis, ESKD occurred significantly more frequently in ANCA-positive patients than in ANCA-negative patients. Among the five subsequent advanced systemic complications of MPA and GPA, ANCA-negative patients exhibited a significantly higher cumulative ESKD-free survival rate than ANCA-positive patients. However, in multivariable Cox proportional hazards analysis adjusted for age, sex, AAV subtype, and baseline serum creatinine, ANCA positivity was not independently associated with subsequent ESKD. Conclusions: Any ANCA positivity at diagnosis was associated with subsequent ESKD in unadjusted analyses but was not an independent predictor after adjustment for baseline renal function and other clinically relevant covariates.
- 27 July 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (9) , 5689-5698
Association of the first-year cumulative vascular damage index with relapse risk in granulomatosis with polyangiitis: a retrospective cohort analysis
Objectives To evaluate whether the first-year cumulative vascular damage index (VDI) could serve as an independent predictor of relapse in patients with granulomatosis with polyangiitis (GPA). Methods We retrospectively analysed 39 patients with GPA enrolled in a single-centre cohort. The first-year cumulative VDI was calculated as the area under the curve (AUC) of VDI scores during the first year using the trapezoidal rule. The earliest VDI, defined as the first VDI recorded ≥ 3 months after AAV diagnosis or AAV symptom onset, was also assessed as a contextual reference. Relapse was defined as the recurrence or new onset of vasculitic manifestations after ≥ 3 months of remission. The predictive accuracy for relapse was assessed using receiver operating characteristic (ROC) curves. Multivariable Cox proportional hazard models were performed to assess whether the first-year cumulative VDI is independently associated with the risk of relapse. Results During a median follow-up of 40.6 (13.9–64.7) months, relapse occurred in 18 (46.2%) patients. The first-year cumulative VDI (AUC = 0.817) showed a significant predictive value for relapse, with a numerically higher accuracy than the earliest VDI (AUC = 0.734), although the difference was not statistically significant (p = 0.272). In the multivariable Cox model, the first-year cumulative VDI was significantly associated with relapse risk (adjusted hazard ratio [HR] = 6.536, 95% confidence interval [CI] = 1.746–24.460, p = 0.005), whereas the earliest VDI was not (adjusted HR = 1.358, 95% CI = 0.976–1.889, p = 0.070). Conclusion The first-year cumulative VDI independently predicts relapse in GPA, and outperformed early single time-point damage assessment. Our findings suggest that early cumulative damage evaluation may improve relapse risk stratification. Key Points • We assessed whether VDI can predict relapse in patients with GPA. • The first-year cumulative VDI was found to independently predict relapse in GPA. • Early cumulative damage evaluation may improve relapse risk stratification.
- 27 July 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (9) , 5689-5698
Association of the first-year cumulative vascular damage index with relapse risk in granulomatosis with polyangiitis: a retrospective cohort analysis
Objectives To evaluate whether the first-year cumulative vascular damage index (VDI) could serve as an independent predictor of relapse in patients with granulomatosis with polyangiitis (GPA). Methods We retrospectively analysed 39 patients with GPA enrolled in a single-centre cohort. The first-year cumulative VDI was calculated as the area under the curve (AUC) of VDI scores during the first year using the trapezoidal rule. The earliest VDI, defined as the first VDI recorded ≥ 3 months after AAV diagnosis or AAV symptom onset, was also assessed as a contextual reference. Relapse was defined as the recurrence or new onset of vasculitic manifestations after ≥ 3 months of remission. The predictive accuracy for relapse was assessed using receiver operating characteristic (ROC) curves. Multivariable Cox proportional hazard models were performed to assess whether the first-year cumulative VDI is independently associated with the risk of relapse. Results During a median follow-up of 40.6 (13.9–64.7) months, relapse occurred in 18 (46.2%) patients. The first-year cumulative VDI (AUC = 0.817) showed a significant predictive value for relapse, with a numerically higher accuracy than the earliest VDI (AUC = 0.734), although the difference was not statistically significant (p = 0.272). In the multivariable Cox model, the first-year cumulative VDI was significantly associated with relapse risk (adjusted hazard ratio [HR] = 6.536, 95% confidence interval [CI] = 1.746–24.460, p = 0.005), whereas the earliest VDI was not (adjusted HR = 1.358, 95% CI = 0.976–1.889, p = 0.070). Conclusion The first-year cumulative VDI independently predicts relapse in GPA, and outperformed early single time-point damage assessment. Our findings suggest that early cumulative damage evaluation may improve relapse risk stratification. Key Points • We assessed whether VDI can predict relapse in patients with GPA. • The first-year cumulative VDI was found to independently predict relapse in GPA. • Early cumulative damage evaluation may improve relapse risk stratification.
- Open Access
Association Between the Earliest CALLY Index at Diagnosis and Progression to End-Stage Kidney Disease in Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Background and Objectives: This study aimed to determine whether the earliest C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index at diagnosis was associated with progression to end-stage kidney disease (ESKD) during follow-up in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: This study included 247 patients with MPA and GPA. The CALLY index was calculated as follows: serum albumin (g/L) × lymphocyte count (/mm3)/CRP (mg/L)/10,000. The earliest CALLY index was defined as the value calculated at diagnosis. ESKD, which occurred after diagnosis, was defined as a poor outcome in this study. Results: The median age of the 247 patients was 62.0 years and 64.4% were women. Among the 247 patients, 50 (20.2%) progressed to ESKD. The earliest CALLY index at diagnosis was significantly lower in patients with ESKD than those without ESKD (0.15 vs. 0.55). Receiver operating characteristic curve analysis showed that the earliest CALLY index had modest discriminatory performance for progression to ESKD, with an area under the curve of 0.663 and a cut-off value of 0.26. Patients with an earliest CALLY index ≤ 0.26 at diagnosis exhibited a significantly higher risk for progression to ESKD (relative risk 3.174) and a significantly reduced cumulative ESKD-free survival rate compared to those with an earliest CALLY index > 0.26 at diagnosis. Conclusions: This study has exploratory implications, as it is the first to report that the earliest CALLY index was associated with ESKD occurrence during follow-up in patients with MPA and GPA, despite its limited value as an independent predictor of ESKD.
Open AccessAssociation Between the Earliest CALLY Index at Diagnosis and Progression to End-Stage Kidney Disease in Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Background and Objectives: This study aimed to determine whether the earliest C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index at diagnosis was associated with progression to end-stage kidney disease (ESKD) during follow-up in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: This study included 247 patients with MPA and GPA. The CALLY index was calculated as follows: serum albumin (g/L) × lymphocyte count (/mm3)/CRP (mg/L)/10,000. The earliest CALLY index was defined as the value calculated at diagnosis. ESKD, which occurred after diagnosis, was defined as a poor outcome in this study. Results: The median age of the 247 patients was 62.0 years and 64.4% were women. Among the 247 patients, 50 (20.2%) progressed to ESKD. The earliest CALLY index at diagnosis was significantly lower in patients with ESKD than those without ESKD (0.15 vs. 0.55). Receiver operating characteristic curve analysis showed that the earliest CALLY index had modest discriminatory performance for progression to ESKD, with an area under the curve of 0.663 and a cut-off value of 0.26. Patients with an earliest CALLY index ≤ 0.26 at diagnosis exhibited a significantly higher risk for progression to ESKD (relative risk 3.174) and a significantly reduced cumulative ESKD-free survival rate compared to those with an earliest CALLY index > 0.26 at diagnosis. Conclusions: This study has exploratory implications, as it is the first to report that the earliest CALLY index was associated with ESKD occurrence during follow-up in patients with MPA and GPA, despite its limited value as an independent predictor of ESKD.
- Open Access
- 29 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Clinical Effectiveness of Dupilumab in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Observational Study
Background: Dupilumab, a monoclonal antibody targeting the interleukin‐4 receptor alpha subunit, has shown efficacy in eosinophilic disorders; however, its role in eosinophilic granulomatosis with polyangiitis (EGPA) remains uncertain. This study compared the clinical outcomes of patients with EGPA treated with conventional therapy, with or without dupilumab, focussing on its effects on disease activity and vasculitic phenotypes. Patients and Methods: From a prospective, single‐centre cohort of patients with antineutrophil cytoplasmic antibody‐associated vasculitis, we retrospectively selected three patients with EGPA who received conventional therapy with dupilumab and six age‐ and sex‐matched patients who received conventional therapy without dupilumab. The Birmingham Vasculitis Activity Score (BVAS), peripheral eosinophil count, erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) levels were assessed at EGPA diagnosis, dupilumab initiation and last follow‐up. Changes in vascular manifestations before and after dupilumab treatment were evaluated. Results: The eosinophilic conditions for which dupilumab was initiated were well controlled in all three patients receiving the drug. In contrast, two of the six patients who did not receive dupilumab showed worsening eosinophilic manifestations. All three patients demonstrated clinical improvement in EGPA following dupilumab treatment, with reductions in the BVAS, eosinophil count, ESR and CRP levels. No worsening of vasculitic phenotypes was observed, even after prolonged exposure (up to 45 months). Conclusions: Dupilumab may help control the eosinophilic phenotypes of EGPA, thereby contributing to overall disease activity control without exacerbating vasculitic phenotypes. However, given the small sample size and retrospective nature of this study, larger prospective trials are required to confirm its efficacy in EGPA.
- 29 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessClinical Effectiveness of Dupilumab in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Observational Study
Background: Dupilumab, a monoclonal antibody targeting the interleukin‐4 receptor alpha subunit, has shown efficacy in eosinophilic disorders; however, its role in eosinophilic granulomatosis with polyangiitis (EGPA) remains uncertain. This study compared the clinical outcomes of patients with EGPA treated with conventional therapy, with or without dupilumab, focussing on its effects on disease activity and vasculitic phenotypes. Patients and Methods: From a prospective, single‐centre cohort of patients with antineutrophil cytoplasmic antibody‐associated vasculitis, we retrospectively selected three patients with EGPA who received conventional therapy with dupilumab and six age‐ and sex‐matched patients who received conventional therapy without dupilumab. The Birmingham Vasculitis Activity Score (BVAS), peripheral eosinophil count, erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) levels were assessed at EGPA diagnosis, dupilumab initiation and last follow‐up. Changes in vascular manifestations before and after dupilumab treatment were evaluated. Results: The eosinophilic conditions for which dupilumab was initiated were well controlled in all three patients receiving the drug. In contrast, two of the six patients who did not receive dupilumab showed worsening eosinophilic manifestations. All three patients demonstrated clinical improvement in EGPA following dupilumab treatment, with reductions in the BVAS, eosinophil count, ESR and CRP levels. No worsening of vasculitic phenotypes was observed, even after prolonged exposure (up to 45 months). Conclusions: Dupilumab may help control the eosinophilic phenotypes of EGPA, thereby contributing to overall disease activity control without exacerbating vasculitic phenotypes. However, given the small sample size and retrospective nature of this study, larger prospective trials are required to confirm its efficacy in EGPA.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (20) , e140
The SHIPE Index: A Tertile-Based Approach to Predict End-Stage Kidney Disease in ANCA-Associated Vasculitis
Do H, et al. J Korean Med Sci. 2026 Jun;41:e140. https://doi.org/10.3346/jkms.2026.41.e140
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (20) , e140
Open AccessThe SHIPE Index: A Tertile-Based Approach to Predict End-Stage Kidney Disease in ANCA-Associated Vasculitis
Do H, et al. J Korean Med Sci. 2026 Jun;41:e140. https://doi.org/10.3346/jkms.2026.41.e140